MX2013004371A - Cisteina y consumo de alimentos. - Google Patents

Cisteina y consumo de alimentos.

Info

Publication number
MX2013004371A
MX2013004371A MX2013004371A MX2013004371A MX2013004371A MX 2013004371 A MX2013004371 A MX 2013004371A MX 2013004371 A MX2013004371 A MX 2013004371A MX 2013004371 A MX2013004371 A MX 2013004371A MX 2013004371 A MX2013004371 A MX 2013004371A
Authority
MX
Mexico
Prior art keywords
cisteine
food consumption
malnutrition
prevention
treatment
Prior art date
Application number
MX2013004371A
Other languages
English (en)
Spanish (es)
Inventor
Karine Vidal
Denis Breuille
Isabelle Papet
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43304791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013004371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013004371A publication Critical patent/MX2013004371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2013004371A 2010-10-21 2011-10-19 Cisteina y consumo de alimentos. MX2013004371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10188399A EP2444083A1 (en) 2010-10-21 2010-10-21 Cysteine and food intake
PCT/EP2011/068231 WO2012052463A1 (en) 2010-10-21 2011-10-19 Cysteine and food intake

Publications (1)

Publication Number Publication Date
MX2013004371A true MX2013004371A (es) 2013-08-27

Family

ID=43304791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004371A MX2013004371A (es) 2010-10-21 2011-10-19 Cisteina y consumo de alimentos.

Country Status (15)

Country Link
US (1) US9233090B2 (enExample)
EP (2) EP2444083A1 (enExample)
JP (1) JP6160832B2 (enExample)
CN (1) CN103269697A (enExample)
AU (1) AU2011317627B2 (enExample)
BR (1) BR112013009709A2 (enExample)
CA (1) CA2815109C (enExample)
DK (1) DK2629769T3 (enExample)
ES (1) ES2654344T3 (enExample)
MX (1) MX2013004371A (enExample)
PH (1) PH12013500761A1 (enExample)
RU (1) RU2013123062A (enExample)
SG (1) SG189935A1 (enExample)
WO (1) WO2012052463A1 (enExample)
ZA (1) ZA201303656B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
CN111315239A (zh) * 2017-11-21 2020-06-19 雀巢产品有限公司 针对肌肉质量和/或肌肉量使用橄榄苦苷或姜黄素的组合物和方法
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2020163188A1 (en) * 2019-02-08 2020-08-13 Imbria Pharmaceuticals, Inc. Compositions containing n-acetylcysteine conjugated to a tca cycle intermediate
EP4049672A4 (en) * 2019-10-25 2023-11-29 Ajinomoto Co., Inc. Muscle quality improvement agent
US20260102441A1 (en) 2022-09-30 2026-04-16 Evonik Operations Gmbh Probiotic composition for the treatment of malnutrition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
JPS62286923A (ja) * 1986-06-04 1987-12-12 Takao Shinoda 貧食作用増強剤
JPH05294833A (ja) * 1991-04-15 1993-11-09 Takeda Chem Ind Ltd ビタミン含有保健剤
WO1993002682A1 (en) 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Method and compositions for reducing craving for alcohol and stimulants
DE4229166A1 (de) * 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
FR2711529B1 (fr) 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
US5627152A (en) * 1995-01-18 1997-05-06 Telluride Pharmaceutical Corporation Method for increasing bodyweight
US5770217A (en) 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
RO119122B1 (ro) * 1998-02-02 2004-04-30 Dumitru Dobrescu Medicament geriatric
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
BR0207948A (pt) * 2001-03-09 2004-07-27 Produits Nestel S A Soc D Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2006134135A2 (en) 2005-06-14 2006-12-21 Nestec S.A. Nutritional method for elderly people
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
JP2009001507A (ja) 2007-06-19 2009-01-08 Ss Pharmaceut Co Ltd 体脂肪減少剤およびその利用
WO2009157759A1 (en) * 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
TWI515005B (zh) * 2008-09-12 2016-01-01 ２４５８７８１加拿大公司 在接受化療或放療的患者中應用富含半胱胺酸之乳清衍生蛋白以增進患者存活時間
SG185344A1 (en) 2008-10-17 2012-11-29 Nestec Sa Whey protein compositions, methods and uses

Also Published As

Publication number Publication date
EP2444083A1 (en) 2012-04-25
BR112013009709A2 (pt) 2016-07-19
ZA201303656B (en) 2014-11-26
US9233090B2 (en) 2016-01-12
RU2013123062A (ru) 2014-11-27
CN103269697A (zh) 2013-08-28
PH12013500761A1 (en) 2017-08-23
SG189935A1 (en) 2013-06-28
AU2011317627B2 (en) 2016-06-02
WO2012052463A1 (en) 2012-04-26
CA2815109C (en) 2020-03-24
DK2629769T3 (en) 2018-01-02
JP2014504261A (ja) 2014-02-20
EP2629769A1 (en) 2013-08-28
US20130225486A1 (en) 2013-08-29
ES2654344T3 (es) 2018-02-13
CA2815109A1 (en) 2012-04-26
AU2011317627A1 (en) 2013-05-23
JP6160832B2 (ja) 2017-07-12
EP2629769B1 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
AU2008313418A8 (en) Composition for regulating lipid metabolism
ATE511764T1 (de) Silizium enthaltende lebensmittel
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
MX2019014247A (es) Composicion de sabor y composiciones comestibles que contienen las mismas.
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
BR112015029487A8 (pt) rebaudiosídeo-e e produtos alimentícios adoçados com rebaudiosídeo-e
NO20075009L (no) Ernaeringstilsetning for HIV-pasienter
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY33405A (es) Composiciones y bebidas que comprenden nutrientes, vitaminas, azúcares, cisteína y/o productos de azúcar-cisteína
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
IN2014CN00795A (enExample)
PH12013500761A1 (en) Cysteine and food intake
UY32638A (es) Manoproteínas para uso en zumo de frutas
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин
PH12015502242A1 (en) Lutein composition suitable for infant food formulations
TR200909786A1 (tr) Sefiksim içeren efervesan tablet ve granül formülasyonu.
NZ713440A (en) Nsaid administration and related compositions, methods and systems.
MX2016015114A (es) Producto de avena enriquecido con avenatramidas.
PL413830A1 (pl) Kompleks laktoferyny z jonami manganu, sposób jego otrzymywania, zastosowanie kompleksu oraz kompozycja farmaceutyczna zawierająca kompleks laktoferyny i jonów manganu
MX384123B (es) Nutrición infantil para el mejoramiento en la sensibilidad a la insulina más adelante en la vida.
WO2010086736A3 (en) Use of the combination of resveratrol with cysteine and derivatives thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal